title: Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.
abstract: Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1862, USA. kirkwoodjm@upmc.edu
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: Ahmad
authors.initials: A
authors.lastname: Tarhini
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.forename: Prapti
authors.initials: P
authors.lastname: Patel
authors.forename: Joan H
authors.initials: JH
authors.lastname: Schiller
authors.forename: Maxwell T
authors.initials: MT
authors.lastname: Vergo
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson Iii
authors.forename: Hussein
authors.initials: H
authors.lastname: Tawbi
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal